<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20241023101022&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20241023101022&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 23 Oct 2024 14:10:24 +0000</lastbuilddate>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Salt Responsive Gut Microbiota Induces Sex Specific Blood Pressure Changes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39440438/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We uncovered a novel sex-specific mechanism in the gut microbiota-mediated tryptophan-indole pathway in blood pressure regulation. Salt tipped the tryptophan metabolism between the host and gut microbiota in a sex-dependent manner. Our study provides evidence for a novel concept that gut microbiota and its metabolism play sex-specific roles in the development of salt-sensitive hypertension.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 23. doi: 10.1161/CIRCRESAHA.124.325056. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Tryptophan metabolism is important in blood pressure regulation. The tryptophan-indole pathway is exclusively mediated by the gut microbiota. ACE2 (angiotensin-converting enzyme 2) participates in tryptophan absorption, and a lack of ACE2 leads to changes in the gut microbiota. The gut microbiota has been recognized as a regulator of blood pressure. Furthermore, there is ample evidence for sex differences in the gut microbiota. However, it is unclear whether such sex differences impact blood pressure differentially through the tryptophan-indole pathway.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To study the sex-specific mechanisms of gut microbiota-mediated tryptophan-indole pathway in hypertension, we generated a novel rat model with Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9)-targeted deletion of <i>Ace2</i> in the Dahl salt-sensitive rat. Cecal microbiota transfers from donors of both sexes to female S recipients were performed. Also, Dahl salt-sensitive rats of both sexes were orally gavaged with indole to investigate blood pressure response.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The female gut microbiota and its tryptophan-indole pathway exhibited greater buffering capacity when exposed to tryptophan, due to <i>Ace2</i> deficiency, and salt. In contrast, the male gut microbiota and its tryptophan-indole pathway were more vulnerable. Female rats with male cecal microbiota responded to salt with a higher blood pressure increase. Indole, a tryptophan-derived metabolite produced by gut bacteria, increased blood pressure in male but not in female rats. Moreover, salt altered host-mediated tryptophan metabolism, characterized by reduced serum serotonin of both sexes and higher levels of kynurenine derivatives in the females.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We uncovered a novel sex-specific mechanism in the gut microbiota-mediated tryptophan-indole pathway in blood pressure regulation. Salt tipped the tryptophan metabolism between the host and gut microbiota in a sex-dependent manner. Our study provides evidence for a novel concept that gut microbiota and its metabolism play sex-specific roles in the development of salt-sensitive hypertension.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39440438/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39440438</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325056>10.1161/CIRCRESAHA.124.325056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39440438</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Pritam Bardhan</dc:creator>
<dc:creator>Xue Mei</dc:creator>
<dc:creator>Ngoc Khanh Lai</dc:creator>
<dc:creator>Blair Mell</dc:creator>
<dc:creator>Ramakumar Tummala</dc:creator>
<dc:creator>Sachin Aryal</dc:creator>
<dc:creator>Ishan Manandhar</dc:creator>
<dc:creator>Hyeongu Hwang</dc:creator>
<dc:creator>Tania Akter Jhuma</dc:creator>
<dc:creator>Rohit R Atluri</dc:creator>
<dc:creator>Jun Kyoung</dc:creator>
<dc:creator>Ying Li</dc:creator>
<dc:creator>Bina Joe</dc:creator>
<dc:creator>Hong-Bao Li</dc:creator>
<dc:creator>Tao Yang</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Salt Responsive Gut Microbiota Induces Sex Specific Blood Pressure Changes</dc:title>
<dc:identifier>pmid:39440438</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325056</dc:identifier>
</item>
<item>
<title>Conduction Disturbances and Outcome After Surgical Aortic Valve Replacement in Patients With Bicuspid and Tricuspid Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39440421/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: New-onset LBBB after SAVR is associated with increased all-cause mortality during follow-up, and is more frequent complication in BAV AS patients compared with TAV-AS patients. BAV-AS patients with fusion of the right- and non-coronary cusps have an increased risk for conduction disturbances after SAVR. This should be taken into consideration when managing these patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 23. doi: 10.1161/CIRCULATIONAHA.124.070753. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valve (BAV) aortic stenosis (AS) versus patients with tricuspid aortic valve (TAV) AS (ie, BAV-AS and TAV-AS, respectively). Additionally, the study included stratification of BAV patients according to subtype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this cohort study, the incidence of postoperative third-degree atrioventricular (AV) block with subsequent permanent pacemaker requirement and new-onset left bundle-branch block (LBBB) was investigated in 1147 consecutive patients without preoperative conduction disorder who underwent isolated SAVR (with or without ascending aortic surgery) between January 1, 2005, and December 31, 2022. The groups were stratified by aortic valve morphology (BAV, n=589; TAV, n=558). The outcomes of interests were new-onset third-degree AV block or new-onset LBBB during the index hospitalization. The impact of new-onset postoperative conduction disturbances on survival was investigated in BAV-AS and TAV-AS patients during a median follow-up of 8.2 years. BAV morphology was further categorized according to the Sievers and Schmidtke classification system (possible in 307 BAV-AS patients) to explore association between BAV subtypes and new-onset conduction disturbances after SAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The overall incidence of third-degree AV block and new-onset LBBB after SAVR was 4.5% and 7.8%, respectively. BAV-AS patients had a higher incidence of both new-onset third-degree AV block (6.5% versus 2.5%; <i>P</i>=0.001) and new-onset LBBB (9.7% versus 5.7%; <i>P</i>=0.013) compared with TAV-AS patients. New-onset LBBB was associated with an increased all-cause mortality during follow-up (adjusted hazard ratio, 1.60 [95% CI, 1.12-2.30]; <i>P</i>=0.011), whereas new-onset third-degree AV block was not associated with worse prognosis. Subgroup analysis of the BAV cohort revealed that BAV-AS patients with fusion of the right- and non-coronary cusps had the highest risk of new-onset third-degree AV block (adjusted odds ratio [aOR], 8.33 [95% CI, 3.31-20.97]; <i>P</i>&lt;0.001, with TAV as reference group) and new-onset LBBB (aOR, 4.03 [95% CI, 1.84-8.82]; <i>P</i>&lt;0.001, with TAV as reference group), whereas no significant association was observed for the other BAV subtypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: New-onset LBBB after SAVR is associated with increased all-cause mortality during follow-up, and is more frequent complication in BAV AS patients compared with TAV-AS patients. BAV-AS patients with fusion of the right- and non-coronary cusps have an increased risk for conduction disturbances after SAVR. This should be taken into consideration when managing these patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39440421/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39440421</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070753>10.1161/CIRCULATIONAHA.124.070753</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39440421</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Johan O Wedin</dc:creator>
<dc:creator>Viktor Näslund</dc:creator>
<dc:creator>Sergey Rodin</dc:creator>
<dc:creator>Oscar E Simonson</dc:creator>
<dc:creator>Frank A Flachskampf</dc:creator>
<dc:creator>Stefan K James</dc:creator>
<dc:creator>Elisabeth Ståhle</dc:creator>
<dc:creator>Karl-Henrik Grinnemo</dc:creator>
<dc:date>2024-10-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Conduction Disturbances and Outcome After Surgical Aortic Valve Replacement in Patients With Bicuspid and Tricuspid Aortic Stenosis</dc:title>
<dc:identifier>pmid:39440421</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070753</dc:identifier>
</item>
<item>
<title>P-stalk ribosomes act as master regulators of cytokine-mediated processes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39437780/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>Inflammatory cytokines are pivotal to immune responses. Upon cytokine exposure, cells enter an "alert state" that enhances their visibility to the immune system. Here, we identified an alert-state subpopulation of ribosomes defined by the presence of the P-stalk. We show that P-stalk ribosomes (PSRs) are formed in response to cytokines linked to tumor immunity, and this is at least partially mediated by P-stalk phosphorylation. PSRs are involved in the preferential translation of mRNAs vital for...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 14:S0092-8674(24)01139-5. doi: 10.1016/j.cell.2024.09.039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Inflammatory cytokines are pivotal to immune responses. Upon cytokine exposure, cells enter an "alert state" that enhances their visibility to the immune system. Here, we identified an alert-state subpopulation of ribosomes defined by the presence of the P-stalk. We show that P-stalk ribosomes (PSRs) are formed in response to cytokines linked to tumor immunity, and this is at least partially mediated by P-stalk phosphorylation. PSRs are involved in the preferential translation of mRNAs vital for the cytokine response via the more efficient translation of transmembrane domains of receptor molecules involved in cytokine-mediated processes. Importantly, loss of the PSR inhibits CD8+ T cell recognition and killing, and inhibitory cytokines like transforming growth factor β (TGF-β) hinder PSR formation, suggesting that the PSR is a central regulatory hub upon which multiple signals converge. Thus, the PSR is an essential mediator of the cellular rewiring that occurs following cytokine exposure via the translational regulation of this process.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39437780/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39437780</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.039>10.1016/j.cell.2024.09.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39437780</guid>
<pubDate>Tue, 22 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Anna Dopler</dc:creator>
<dc:creator>Ferhat Alkan</dc:creator>
<dc:creator>Yuval Malka</dc:creator>
<dc:creator>Rob van der Kammen</dc:creator>
<dc:creator>Kelly Hoefakker</dc:creator>
<dc:creator>Daniel Taranto</dc:creator>
<dc:creator>Naz Kocabay</dc:creator>
<dc:creator>Iris Mimpen</dc:creator>
<dc:creator>Christel Ramirez</dc:creator>
<dc:creator>Elke Malzer</dc:creator>
<dc:creator>Olga I Isaeva</dc:creator>
<dc:creator>Mandy Kerkhoff</dc:creator>
<dc:creator>Anastasia Gangaev</dc:creator>
<dc:creator>Joana Silva</dc:creator>
<dc:creator>Sofia Ramalho</dc:creator>
<dc:creator>Liesbeth Hoekman</dc:creator>
<dc:creator>Maarten Altelaar</dc:creator>
<dc:creator>Roderick Beijersbergen</dc:creator>
<dc:creator>Leila Akkari</dc:creator>
<dc:creator>Jonathan Wilson Yewdell</dc:creator>
<dc:creator>Pia Kvistborg</dc:creator>
<dc:creator>William James Faller</dc:creator>
<dc:date>2024-10-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>P-stalk ribosomes act as master regulators of cytokine-mediated processes</dc:title>
<dc:identifier>pmid:39437780</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.039</dc:identifier>
</item>
<item>
<title>Potent efficacy of an IgG-specific endoglycosidase against IgG-mediated pathologies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39437779/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>Endo-β-N-acetylglucosaminidases (ENGases) that specifically hydrolyze the Asn297-linked glycan on immunoglobulin G (IgG) antibodies, the major molecular determinant of fragment crystallizable (Fc) γ receptor (FcγR) binding, are exceedingly rare. All previously characterized IgG-specific ENGases are multi-domain proteins secreted as an immune evasion strategy by Streptococcus pyogenes strains. Here, using in silico analysis and mass spectrometry techniques, we identified a family of single-domain...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 17:S0092-8674(24)01135-8. doi: 10.1016/j.cell.2024.09.038. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Endo-β-N-acetylglucosaminidases (ENGases) that specifically hydrolyze the Asn297-linked glycan on immunoglobulin G (IgG) antibodies, the major molecular determinant of fragment crystallizable (Fc) γ receptor (FcγR) binding, are exceedingly rare. All previously characterized IgG-specific ENGases are multi-domain proteins secreted as an immune evasion strategy by Streptococcus pyogenes strains. Here, using in silico analysis and mass spectrometry techniques, we identified a family of single-domain ENGases secreted by pathogenic corynebacterial species that exhibit strict specificity for IgG antibodies. By X-ray crystallographic and surface plasmon resonance analyses, we found that the most catalytically efficient IgG-specific ENGase family member recognizes both protein and glycan components of IgG. Employing in vivo models, we demonstrated the remarkable efficacy of this IgG-specific ENGase in mitigating numerous pathologies that rely on FcγR-mediated effector functions, including T and B lymphocyte depletion, autoimmune hemolytic anemia, and antibody-dependent enhancement of dengue disease, revealing its potential for treating and/or preventing a wide range of IgG-mediated diseases in humans.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39437779/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39437779</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.038>10.1016/j.cell.2024.09.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39437779</guid>
<pubDate>Tue, 22 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Diego E Sastre</dc:creator>
<dc:creator>Stylianos Bournazos</dc:creator>
<dc:creator>Jonathan Du</dc:creator>
<dc:creator>E Josephine Boder</dc:creator>
<dc:creator>Julia E Edgar</dc:creator>
<dc:creator>Tala Azzam</dc:creator>
<dc:creator>Nazneen Sultana</dc:creator>
<dc:creator>Maros Huliciak</dc:creator>
<dc:creator>Maria Flowers</dc:creator>
<dc:creator>Lea Yoza</dc:creator>
<dc:creator>Ting Xu</dc:creator>
<dc:creator>Tatiana A Chernova</dc:creator>
<dc:creator>Jeffrey V Ravetch</dc:creator>
<dc:creator>Eric J Sundberg</dc:creator>
<dc:date>2024-10-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Potent efficacy of an IgG-specific endoglycosidase against IgG-mediated pathologies</dc:title>
<dc:identifier>pmid:39437779</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.038</dc:identifier>
</item>
<item>
<title>An endogenous cholinergic system controls electrical conduction in the heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39437249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study identifies an integrated cholinergic system inherent to the heart, rather than external nerves that can effectively control cardiac electrical conduction. The discovery reveals arrhythmia mechanisms beyond classical theories and opens new directions for arrhythmia research.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 22:ehae699. doi: 10.1093/eurheartj/ehae699. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The cholinergic system is distributed in the nervous system, mediating electrical conduction through acetylcholine (ACh). This study aims to identify whether the heart possesses an intact endogenous cholinergic system and to explore its electrophysiological functions and relationship with arrhythmias in both humans and animals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The components of the heart's endogenous cholinergic system were identified by a combination of multiple molecular cell biology techniques. The relationship of this system with cardiac electrical conduction and arrhythmias was analysed through electrophysiological techniques.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: An intact cholinergic system including ACh, ACh transmitter vesicles, ACh transporters, ACh metabolic enzymes, and ACh receptors was identified in both human and mouse ventricular cardiomyocytes (VCs). The key components of the system significantly regulated the conductivity of electrical excitation among VCs. The influence of this system on electrical excitation conduction was further confirmed both in the mice with α4 or α7 nicotinic ACh receptors (nAChRs) knockouts and in the monolayers of human induced pluripotent stem cell-derived cardiomyocytes. Mechanistically, ACh induced an inward current through nAChRs to reduce the minimum threshold current required to generate an action potential in VCs, thereby enhancing the excitability that acts as a prerequisite for electrical conduction. Importantly, defects in this system were associated with fatal ventricular arrhythmias in both patients and mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study identifies an integrated cholinergic system inherent to the heart, rather than external nerves that can effectively control cardiac electrical conduction. The discovery reveals arrhythmia mechanisms beyond classical theories and opens new directions for arrhythmia research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39437249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39437249</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae699>10.1093/eurheartj/ehae699</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39437249</guid>
<pubDate>Tue, 22 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Duanyang Xie</dc:creator>
<dc:creator>Ke Xiong</dc:creator>
<dc:creator>Nianguo Dong</dc:creator>
<dc:creator>Guanghua Wang</dc:creator>
<dc:creator>Qicheng Zou</dc:creator>
<dc:creator>Beihua Shao</dc:creator>
<dc:creator>Zhiwen Chen</dc:creator>
<dc:creator>Luxin Wang</dc:creator>
<dc:creator>Yu Kong</dc:creator>
<dc:creator>Xu Wang</dc:creator>
<dc:creator>Xuling Su</dc:creator>
<dc:creator>Wenli Bai</dc:creator>
<dc:creator>Jian Yang</dc:creator>
<dc:creator>Yi Liu</dc:creator>
<dc:creator>Bin Zhou</dc:creator>
<dc:creator>Yi-Han Chen</dc:creator>
<dc:date>2024-10-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>An endogenous cholinergic system controls electrical conduction in the heart</dc:title>
<dc:identifier>pmid:39437249</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae699</dc:identifier>
</item>
<item>
<title>Bleeding After Cardiovascular Surgery: A Continuing Problem</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432577/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1324-1326. doi: 10.1161/CIRCULATIONAHA.124.071147. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432577/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39432577</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11495651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">PMC11495651</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071147>10.1161/CIRCULATIONAHA.124.071147</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432577</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Frank W Sellke</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Bleeding After Cardiovascular Surgery: A Continuing Problem</dc:title>
<dc:identifier>pmid:39432577</dc:identifier>
<dc:identifier>pmc:PMC11495651</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071147</dc:identifier>
</item>
<item>
<title>Partial Heart Transplantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1313-1314. doi: 10.1161/CIRCULATIONAHA.124.071498. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39432576</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071498>10.1161/CIRCULATIONAHA.124.071498</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432576</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Taufiek K Rajab</dc:creator>
<dc:creator>Alekhya Mitta</dc:creator>
<dc:creator>Brian L Reemtsen</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Partial Heart Transplantation</dc:title>
<dc:identifier>pmid:39432576</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071498</dc:identifier>
</item>
<item>
<title>Evolution of Coronary Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432575/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1311-1312. doi: 10.1161/CIRCULATIONAHA.124.070918. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432575/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39432575</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070918>10.1161/CIRCULATIONAHA.124.070918</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432575</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Bruce Lytle</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Evolution of Coronary Surgery</dc:title>
<dc:identifier>pmid:39432575</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070918</dc:identifier>
</item>
<item>
<title>Introduction to the 2024 Cardiovascular Surgery-Themed Issue of &lt;em>;Circulation&lt;/em>;</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1307. doi: 10.1161/CIRCULATIONAHA.124.072090. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39432574</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072090>10.1161/CIRCULATIONAHA.124.072090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432574</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marc Ruel</dc:creator>
<dc:creator>James de Lemos</dc:creator>
<dc:creator>Michael Fischbein</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Introduction to the 2024 Cardiovascular Surgery-Themed Issue of &lt;em>;Circulation&lt;/em>;</dc:title>
<dc:identifier>pmid:39432574</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072090</dc:identifier>
</item>
<item>
<title>Against Odds of Prolonged Warm Ischemia: Early Experience With DCD Heart Transplantation After 20-Minute No-Touch Period</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432573/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1391-1393. doi: 10.1161/CIRCULATIONAHA.124.071239. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432573/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39432573</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071239>10.1161/CIRCULATIONAHA.124.071239</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432573</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gino Gerosa</dc:creator>
<dc:creator>Giovanni Battista Luciani</dc:creator>
<dc:creator>Nicola Pradegan</dc:creator>
<dc:creator>Vincenzo Tarzia</dc:creator>
<dc:creator>Tea Lena</dc:creator>
<dc:creator>Paolo Zanatta</dc:creator>
<dc:creator>Demetrio Pittarello</dc:creator>
<dc:creator>Francesco Onorati</dc:creator>
<dc:creator>Antonella Galeone</dc:creator>
<dc:creator>Leonardo Gottin</dc:creator>
<dc:creator>Massimo Boffini</dc:creator>
<dc:creator>Marinella Zanierato</dc:creator>
<dc:creator>Matteo Marro</dc:creator>
<dc:creator>Sofia Martin Suarez</dc:creator>
<dc:creator>Luca Botta</dc:creator>
<dc:creator>Paola Lilla Della Monica</dc:creator>
<dc:creator>Mariano Feccia</dc:creator>
<dc:creator>Guido Maria Olivieri</dc:creator>
<dc:creator>Amedeo Terzi</dc:creator>
<dc:creator>Alessandra Oliveti</dc:creator>
<dc:creator>Giuseppe Feltrin</dc:creator>
<dc:creator>Massimo Cardillo</dc:creator>
<dc:creator>Claudio Francesco Russo</dc:creator>
<dc:creator>Davide Pacini</dc:creator>
<dc:creator>Mauro Rinaldi</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Against Odds of Prolonged Warm Ischemia: Early Experience With DCD Heart Transplantation After 20-Minute No-Touch Period</dc:title>
<dc:identifier>pmid:39432573</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071239</dc:identifier>
</item>
<item>
<title>Progressive Understanding of Aortic Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432572/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1308-1310. doi: 10.1161/CIRCULATIONAHA.124.070477. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432572/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39432572</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070477>10.1161/CIRCULATIONAHA.124.070477</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432572</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Tara M Mastracci</dc:creator>
<dc:creator>Stéphan Haulon</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Progressive Understanding of Aortic Disease</dc:title>
<dc:identifier>pmid:39432572</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070477</dc:identifier>
</item>
<item>
<title>The Netrod™ six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39431289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae703. doi: 10.1093/eurheartj/ehae703. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39431289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39431289</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae703>10.1093/eurheartj/ehae703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39431289</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yueping Li</dc:creator>
<dc:creator>Fei Gao</dc:creator>
<dc:creator>Changjie Ren</dc:creator>
<dc:creator>Genshan Ma</dc:creator>
<dc:creator>Peili Bu</dc:creator>
<dc:creator>Guosheng Fu</dc:creator>
<dc:creator>Hao Chen</dc:creator>
<dc:creator>Zhanying Han</dc:creator>
<dc:creator>Yan Li</dc:creator>
<dc:creator>Jing Li</dc:creator>
<dc:creator>Xiang Ma</dc:creator>
<dc:creator>Liuyi Hao</dc:creator>
<dc:creator>Yundai Chen</dc:creator>
<dc:creator>Mao Chen</dc:creator>
<dc:creator>Xiaoping Chen</dc:creator>
<dc:creator>Xuebo Liu</dc:creator>
<dc:creator>Jiangang Jiang</dc:creator>
<dc:creator>Jing Yu</dc:creator>
<dc:creator>Nanfang Li</dc:creator>
<dc:creator>Xueping Ma</dc:creator>
<dc:creator>Bin Yang</dc:creator>
<dc:creator>Hongliang Cong</dc:creator>
<dc:creator>Xuekun Wang</dc:creator>
<dc:creator>Qingyong Fan</dc:creator>
<dc:creator>Shuzhi Lv</dc:creator>
<dc:creator>Dongliang Wu</dc:creator>
<dc:creator>Qiming Dai</dc:creator>
<dc:creator>Fuyu Qiu</dc:creator>
<dc:creator>Han Cai</dc:creator>
<dc:creator>Yu-Jie Zhou</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Netrod™ six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial</dc:title>
<dc:identifier>pmid:39431289</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae703</dc:identifier>
</item>
<item>
<title>Arterial-Lymphatic-Like Endothelial Cells Appear in Hereditary Hemorrhagic Telangiectasia 2 and Contribute to Vascular Leakage and Arteriovenous Malformations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429196/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Together, our studies revealed the mechanistic underpinnings of ALK1 signaling in regulating the endothelial phenotype and provided possibilities for new therapeutic strategies in hemorrhagic telangiectasia type 2.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.124.070925. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Arteriovenous malformations (AVMs) are characteristic of hereditary hemorrhagic telangiectasia. Loss-of-function mutations in the activin receptor-like kinase 1 (<i>Alk1</i>) are linked to hemorrhagic telangiectasia type 2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Endothelial-specific deletion of <i>Alk1,</i> endothelial lineage tracing, transcriptomics of single-cell analysis, and electron microscopy were performed to examine the vascular phenotype and characteristics of ALK1-deficient endothelial cells (ECs) after EC-specific <i>Alk1</i> deletion. Ischemia assays were used to examine the cell capacity for vascular malformation. Connectivity Map with transcriptomic analysis was applied to identify chemical compounds. Specific methods for arteriovenous malformations, such as micro-computed tomography, with other molecular and cell biological tools were also performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We performed endothelial-specific deletion of <i>Alk1</i> in mice and found severe arteriovenous malformations and vascular leakage. The transcriptomics of single-cell analysis revealed a new distinctive cell cluster formed after <i>Alk1</i> deletion where the cells coexpressed arterial and lymphatic endothelial markers. The analysis projected that these cells potentially originated from arterial ECs after <i>Alk1</i> deletion. This new population was referred to as arterial-lymphatic-like ECs according to its cellular markers, and its appearance was validated in the pulmonary small arteries after <i>Alk1</i> deletion. Transplantation of these cells caused vascular malformations. Endothelial lineage tracing confirmed that these new arterial-lymphatic-like ECs were derived from ALK1 depleted ECs, potentially arterial ECs. We discovered that SOX17 (SRY-box transcription factor 17) induction was responsible for the derivation of these arterial-lymphatic-like ECs. We showed that direct binding of MDM2 (mouse double minute 2) was required for Sox17 to execute this activity. Inhibition of MDM2 reduced the arteriovenous malformations in the mouse model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Together, our studies revealed the mechanistic underpinnings of ALK1 signaling in regulating the endothelial phenotype and provided possibilities for new therapeutic strategies in hemorrhagic telangiectasia type 2.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429196/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39429196</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070925>10.1161/CIRCULATIONAHA.124.070925</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429196</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yang Yang</dc:creator>
<dc:creator>Xiuju Wu</dc:creator>
<dc:creator>Yan Zhao</dc:creator>
<dc:creator>Daoqin Zhang</dc:creator>
<dc:creator>Li Zhang</dc:creator>
<dc:creator>Xinjiang Cai</dc:creator>
<dc:creator>Jaden Ji</dc:creator>
<dc:creator>Zheng Jing</dc:creator>
<dc:creator>Kristina I Boström</dc:creator>
<dc:creator>Yucheng Yao</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Arterial-Lymphatic-Like Endothelial Cells Appear in Hereditary Hemorrhagic Telangiectasia 2 and Contribute to Vascular Leakage and Arteriovenous Malformations</dc:title>
<dc:identifier>pmid:39429196</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070925</dc:identifier>
</item>
<item>
<title>Cytotoxic T-Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429148/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 21. doi: 10.1161/CIRCRESAHA.124.325183. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429148/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39429148</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325183>10.1161/CIRCRESAHA.124.325183</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429148</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Maurits A Sikking</dc:creator>
<dc:creator>Daniel Harding</dc:creator>
<dc:creator>Michiel T H M Henkens</dc:creator>
<dc:creator>Sophie L V M Stroeks</dc:creator>
<dc:creator>Max F G H M Venner</dc:creator>
<dc:creator>Bastien Nihant</dc:creator>
<dc:creator>Rick E W van Leeuwen</dc:creator>
<dc:creator>Silvia Fanti</dc:creator>
<dc:creator>Xiaofei Li</dc:creator>
<dc:creator>Pieter van Paassen</dc:creator>
<dc:creator>Christian Knackstedt</dc:creator>
<dc:creator>Hans-Peter Brunner-la Rocca</dc:creator>
<dc:creator>Vanessa P M van Empel</dc:creator>
<dc:creator>Job A J Verdonschot</dc:creator>
<dc:creator>Federica M Marelli-Berg</dc:creator>
<dc:creator>Stephane R B Heymans</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cytotoxic T-Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy</dc:title>
<dc:identifier>pmid:39429148</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325183</dc:identifier>
</item>
<item>
<title>Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429145/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with heart failure and preserved ejection fraction, even modest baseline impairment of cognitive function was associated with worse outcomes, including death. A decline in MMSE score during follow-up was a strong predictor of mortality, independent of other prognostic variables.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.124.070553. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We analyzed cognitive function, using the Mini-Mental State Examination (MMSE), in patients with heart failure and preserved ejection fraction enrolled in a prespecified substudy of the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction). Logistic regression analyses were performed to determine the variables associated with lower MMSE scores at baseline and postbaseline decline in MMSE scores at 48 weeks. Cox proportional hazards regression and semiparametric proportional rates models were used to examine the risk of clinical outcomes related to baseline MMSE scores, and decline in MMSE scores during follow-up, adjusted for prognostic variables including NT-proBNP (N-terminal pro-B-type natriuretic peptide).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, cognitive function was normal (MMSE score 28-30) in 1809 of 2895 patients (62.5%), borderline (score 24-27) in 794 (27.4%), and impaired (score &lt;24) in 292 (10.1%). Variables associated with both a lower MMSE score at baseline and a decline in score from baseline included older age, a history of stroke or transient ischemia attack, and lower serum albumin. Compared with those with baseline MMSE scores of 28 to 30, patients in the lower MMSE score categories had a stepwise increase in the risk of the composite of time to first HF hospitalization or cardiovascular death, with an adjusted hazard ratio of 1.27 (95% CI, 1.06-1.53) for those with scores of 24 to 27 and 1.58 (95% CI, 1.21-2.06) for those with scores &lt;24, respectively. These associations were also found for the individual components of the composite and all-cause death. Likewise, cognitive impairment was associated with a 50% higher risk of total (first and repeat) heart failure hospitalizations and cardiovascular deaths. Examining the change in MMSE score from baseline, a decrease in MMSE score during follow-up was associated with a higher risk of death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with heart failure and preserved ejection fraction, even modest baseline impairment of cognitive function was associated with worse outcomes, including death. A decline in MMSE score during follow-up was a strong predictor of mortality, independent of other prognostic variables.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429145/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39429145</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070553>10.1161/CIRCULATIONAHA.124.070553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429145</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Li Shen</dc:creator>
<dc:creator>Pooja Dewan</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:creator>Jonathan W Cunningham</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Inder S Anand</dc:creator>
<dc:creator>Alvin Chandra</dc:creator>
<dc:creator>Lu-May Chiang</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Jianjian Gong</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Martin P Lefkowitz</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Felipe Martinez</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Margaret M Redfield</dc:creator>
<dc:creator>Jean L Rouleau</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF</dc:title>
<dc:identifier>pmid:39429145</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070553</dc:identifier>
</item>
<item>
<title>Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429140/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Increased systemic or local S1P levels lead to increased valvular calcification. S1PR2 antagonists and SphK1 inhibitors may offer feasible pharmacological approaches to human AVD in prophylactic, disease-modifying or relapse-preventing manners.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.123.067270. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Aortic valve disease (AVD) is associated with high mortality and morbidity. To date, there is no pharmacological therapy available to prevent AVD progression. Because valve calcification is the hallmark of AVD and S1P (sphingosine-1-phosphate) plays an important role in osteogenic signaling, we examined the role of S1P signaling in aortic stenosis disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: AVD progression and its consequences for cardiac function were examined in a murine wire injury-induced AVD model with and without pharmacological and genetic modulation of S1P production, degradation, and receptor signaling. S1P was measured by LC-MS. Calcification of valvular interstitial cells and their response to biomechanical stress were analyzed in the context of S1P signaling. Human explanted aortic valves from patients undergoing aortic valve replacement and cardiovascular magnetic resonance imaging were analyzed for S1P by LC-MS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Raising S1P concentrations in mice with injury-induced AVD by pharmacological inhibition of its sole degrading enzyme S1P lyase vastly enhanced AVD progression and impaired cardiac function resembling human disease. In contrast, low S1P levels caused by SphK1 (sphingosine kinase 1) deficiency potently attenuated AVD progression. We found S1P/S1PR2 (S1P receptor 2) signaling to be responsible for the adverse S1P effect because S1PR2-deficient mice were protected against AVD progression and its deterioration by high S1P. It is important to note that pharmacological S1PR2 inhibition administered after wire injury successfully prevented AVD development. Mechanistically, biomechanical stretch stimulated S1P production by SphK1 in human valvular interstitial cells as measured by C17-S1P generation, whereas S1P/S1PR2 signaling induced their osteoblastic differentiation and calcification through osteogenic RUNX2/OPG signaling and the GSK3β-Wnt-β-catenin pathway. In patients with AVD, stenotic valves exposed to high wall shear stress had higher S1P content and increased SphK1 expression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Increased systemic or local S1P levels lead to increased valvular calcification. S1PR2 antagonists and SphK1 inhibitors may offer feasible pharmacological approaches to human AVD in prophylactic, disease-modifying or relapse-preventing manners.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429140/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39429140</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067270>10.1161/CIRCULATIONAHA.123.067270</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429140</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marcel Benkhoff</dc:creator>
<dc:creator>Maike Barcik</dc:creator>
<dc:creator>Philipp Mourikis</dc:creator>
<dc:creator>Jana Dahlmanns</dc:creator>
<dc:creator>Paulina Kahmann</dc:creator>
<dc:creator>Philipp Wollnitzke</dc:creator>
<dc:creator>Moritz Hering</dc:creator>
<dc:creator>Tim Huckenbeck</dc:creator>
<dc:creator>Julia Hoppe</dc:creator>
<dc:creator>Nina Semleit</dc:creator>
<dc:creator>Jennifer Deister-Jonas</dc:creator>
<dc:creator>Saif Zako</dc:creator>
<dc:creator>Jasmin Seel</dc:creator>
<dc:creator>Cristina Coman</dc:creator>
<dc:creator>Mareike Barth</dc:creator>
<dc:creator>Mareike Cramer</dc:creator>
<dc:creator>Carolin Helten</dc:creator>
<dc:creator>Laura Wildeis</dc:creator>
<dc:creator>Hao Hu</dc:creator>
<dc:creator>Gabrielle Al-Kassis</dc:creator>
<dc:creator>Daniel Metzen</dc:creator>
<dc:creator>Julia Hesse</dc:creator>
<dc:creator>Jessica Weber</dc:creator>
<dc:creator>Lisa Dannenberg</dc:creator>
<dc:creator>Payam Akhyari</dc:creator>
<dc:creator>Artur Lichtenberg</dc:creator>
<dc:creator>Christine Quast</dc:creator>
<dc:creator>Norbert Gerdes</dc:creator>
<dc:creator>Tobias Zeus</dc:creator>
<dc:creator>Oliver Borst</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Tobias Petzold</dc:creator>
<dc:creator>Robert Ahrends</dc:creator>
<dc:creator>Bodo Levkau</dc:creator>
<dc:creator>Amin Polzin</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease</dc:title>
<dc:identifier>pmid:39429140</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067270</dc:identifier>
</item>
<item>
<title>Prognosis after switching to electronic cigarettes following percutaneous coronary intervention: a Korean nationwide study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429032/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among smokers who underwent PCI for coronary artery disease, switching to E-cigarette use (particularly complete transition) or quitting smoking was associated with reduced MACE risk than with continued combustible cigarette use.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae705. doi: 10.1093/eurheartj/ehae705. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Despite the increasing popularity of electronic cigarettes (E-cigarettes), the prognostic impact of switching to E-cigarettes in smokers with coronary artery disease who have undergone percutaneous coronary intervention (PCI) remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using a nationwide cohort from the Korean National Health Insurance database, 17 973 adults (≥20 years) identified as smokers (based on a health screening examination within 3 years before PCI) who underwent health screening within 3 years after PCI were enrolled to determine changes in smoking habits. Patients were classified as continued combustible cigarette users, successful quitters, or switchers to E-cigarettes. The group switching to E-cigarettes was further divided into dual users (using both combustible and E-cigarettes) and those exclusively using E-cigarettes. Primary outcomes included major adverse cardiac events (MACEs), a composite of all-cause death, spontaneous myocardial infarction, and repeat revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the total population, 8951 patients (49.8%) continued using combustible cigarettes, 1694 (9.4%) were switched to E-cigarettes, and 7328 (40.7%) successfully quit smoking after PCI. During a median follow-up of 2.4 years, the cumulative incidence of MACE was lower among E-cigarette switchers (10%) or quitters (13.4%) than among continued combustible cigarette users (17%). When continued combustible cigarette users were used as the reference, the multivariable-adjusted hazard ratios with 95% confidence intervals for MACE were 0.82 (0.69-0.98) for switchers to E-cigarettes and 0.87 (0.79-0.96) for successful quitters. Compared with dual users, entirely switching to E-cigarettes was associated with a significantly lower MACE risk (hazard ratio 0.71; 95% confidence interval 0.51-0.99).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among smokers who underwent PCI for coronary artery disease, switching to E-cigarette use (particularly complete transition) or quitting smoking was associated with reduced MACE risk than with continued combustible cigarette use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT06338761.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429032/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39429032</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae705>10.1093/eurheartj/ehae705</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429032</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Danbee Kang</dc:creator>
<dc:creator>Ki Hong Choi</dc:creator>
<dc:creator>Hyunsoo Kim</dc:creator>
<dc:creator>Hyejeong Park</dc:creator>
<dc:creator>Jihye Heo</dc:creator>
<dc:creator>Taek Kyu Park</dc:creator>
<dc:creator>Joo Myung Lee</dc:creator>
<dc:creator>Juhee Cho</dc:creator>
<dc:creator>Jeong Hoon Yang</dc:creator>
<dc:creator>Joo-Yong Hahn</dc:creator>
<dc:creator>Seung-Hyuk Choi</dc:creator>
<dc:creator>Hyeon-Cheol Gwon</dc:creator>
<dc:creator>Young Bin Song</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prognosis after switching to electronic cigarettes following percutaneous coronary intervention: a Korean nationwide study</dc:title>
<dc:identifier>pmid:39429032</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae705</dc:identifier>
</item>
<item>
<title>Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39428997/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The risk of major clinical outcomes did not differ between individuals with and without AF-related symptoms. Asymptomatic patients had a greater hazard of progression to permanent AF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae694. doi: 10.1093/eurheartj/ehae694. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Current guidelines suggest that asymptomatic atrial fibrillation (AF) is independently associated with increased risks of stroke and mortality compared with symptomatic AF. Considering that recent investigations have provided conflicting results, the present study aimed to evaluate the association between symptom status and clinical outcomes in patients with AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Medline, Cochrane Library, and Scopus were searched until 25 March 2024. Triple-independent study selection, data extraction and quality assessment were performed. Evidence was pooled using random-effects meta-analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Thirty-six studies (217 850 participants) were included. Based on the frequentist analysis, symptomatic individuals had no significant difference in the risk of all-cause mortality [hazard ratio (HR) .97, 95% confidence interval (CI) .80-1.17], cardiovascular mortality (HR 1.04, 95% CI .72-1.49), thromboembolism (HR 1.06, 95% CI .87-1.28), stroke (HR 1.06, 95% CI .84-1.34), hospitalization (HR 1.34, 95% CI .89-2.02), and myocardial infarction (HR .98, 95% CI .70-1.36), compared to the asymptomatic group. Symptomatic patients had a 33% increased risk of new-onset heart failure (HR 1.33, 95% CI 1.19-1.49) and a 30% lower risk of progression to permanent AF (HR .70, 95% CI .54-.89). The Bayesian analysis yielded comparable results, yet the association between symptom status and new-onset heart failure was not significant (HR 1.27, 95% credible interval .76-1.93; Bayes factor = 1.2). Symptomatic patients had higher odds of receiving antiarrhythmic drugs (odds ratio [OR] 1.64, 95% CI 1.33-2.03) and ablation therapy (OR 1.47, 95% CI 1.06-2.05) compared to asymptomatic cases.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The risk of major clinical outcomes did not differ between individuals with and without AF-related symptoms. Asymptomatic patients had a greater hazard of progression to permanent AF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39428997/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39428997</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae694>10.1093/eurheartj/ehae694</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39428997</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Paschalis Karakasis</dc:creator>
<dc:creator>Konstantinos Pamporis</dc:creator>
<dc:creator>Konstantinos C Siontis</dc:creator>
<dc:creator>Panagiotis Theofilis</dc:creator>
<dc:creator>Athanasios Samaras</dc:creator>
<dc:creator>Dimitrios Patoulias</dc:creator>
<dc:creator>Panagiotis Stachteas</dc:creator>
<dc:creator>Efstratios Karagiannidis</dc:creator>
<dc:creator>George Stavropoulos</dc:creator>
<dc:creator>Apostolos Tzikas</dc:creator>
<dc:creator>George Kassimis</dc:creator>
<dc:creator>George Giannakoulas</dc:creator>
<dc:creator>Theodoros Karamitsos</dc:creator>
<dc:creator>Demosthenes G Katritsis</dc:creator>
<dc:creator>Nikolaos Fragakis</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis</dc:title>
<dc:identifier>pmid:39428997</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae694</dc:identifier>
</item>
<item>
<title>Changing of the guard at the European Society of Cardiology's prevention journal</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39428580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae642. doi: 10.1093/eurheartj/ehae642. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39428580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39428580</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae642>10.1093/eurheartj/ehae642</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39428580</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Taylor</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Changing of the guard at the European Society of Cardiology's prevention journal</dc:title>
<dc:identifier>pmid:39428580</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae642</dc:identifier>
</item>
<item>
<title>Peerless performance: celebrating the backstage champions of scientific publishing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39428576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae662. doi: 10.1093/eurheartj/ehae662. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39428576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39428576</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae662>10.1093/eurheartj/ehae662</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39428576</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Peerless performance: celebrating the backstage champions of scientific publishing</dc:title>
<dc:identifier>pmid:39428576</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae662</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Anna Strömberg</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39428569/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241023101022&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae629. doi: 10.1093/eurheartj/ehae629. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39428569/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241023101022&v=2.18.0.post9+e462414">39428569</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae629>10.1093/eurheartj/ehae629</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39428569</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Anna Strömberg</dc:title>
<dc:identifier>pmid:39428569</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae629</dc:identifier>
</item>





























</channel>
</rss>